Stay updated on Surufatinib in Biliary Tract Carcinoma: Clinical Trial

Sign up to get notified when there's something new on the Surufatinib in Biliary Tract Carcinoma: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Surufatinib in Biliary Tract Carcinoma: Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest has been deleted.
    Difference
    0.9%
    Check dated 2025-07-04T00:54:57.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.7%
    Check dated 2025-06-19T17:19:46.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-12T13:24:08.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, and API users can provide input before this change. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T06:12:29.000Z thumbnail image
  6. Check
    71 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T18:04:05.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    The page has undergone significant changes, including the removal of detailed descriptions of a clinical study on surufatinib versus Capecitabine for biliary tract cancer, and the addition of a new version revision number. The study's inclusion and exclusion criteria have also been altered, impacting the understanding of the study's parameters.
    Difference
    52%
    Check dated 2025-04-16T12:51:23.000Z thumbnail image

Stay in the know with updates to Surufatinib in Biliary Tract Carcinoma: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Surufatinib in Biliary Tract Carcinoma: Clinical Trial page.